图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-22-099758 Act: 34 Size: 143 KB 网页链接
$Karyopharm(KPTI)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-22-005492 Act: 34 Size: 4 MB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-021755 Size: 8 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001193125-22-087458 Act: 34 Size: 350 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, item 5.02 Accession Number: 0001193125-22-086854 Act: 34 Size: 141 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-014628 Size: 9 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-014629 Size: 9 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-014626 Size: 12 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-014622 Size: 7 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-014623 Size: 7 KB 网页链接